Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Key Pathway in Antibody B-Cell Production Identified, Important to Diseases Like MS

Scientists discovered two key players — TBK1 and ICOS — that control the effective production of antibodies and may offer new insights into potential therapies for autoimmune diseases, including multiple sclerosis. The study, “A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1,” was published in the journal Nature Immunology.

Follicular helper T-cells (Tfh cells) are a rare type of T-cells with key functions in our immune system. Specifically, they promote the proliferation of antibody-producing cells, called B-cells.

A research team at La Jolla Institute for Allergy and Immunology discovered the signal that drives maturation of Tfh cells, from an immature to a mature state in which they are fully functional. The signal is an enzyme called TANK-binding kinase 1 (TBK1), the researchers reported in a study led by La Jolla Institute Professor Shane Crotty, PhD, and Instructor Kok-Fai Kong, PhD. TBK1 controls the maturation of antibodies by associating with a second partner, the Inducible T cell Co-Stimulator (ICOS).

ICOS was previously reported as an essential factor for most Tfh cell functions, but its mechanisms were unknown. A better and deeper understanding of ICOS will allow scientists to manipulate and achieve more specific antibody production. This could lead to more efficient vaccines and better treatments for immune disorders like multiple sclerosis.

“Tfh cells have recently been recognized as important players in the immune system, and we now know they are essential for almost all antibody responses. Tfh cells control the whole process of generating high affinity antibodies, and ICOS is a receptor molecule strongly required for Tfh cells to work. Understand ICOS better, and you can make more Tfh when needed, and block it when not needed,” Dr. Crotty said in a press release.

“We were looking to find out a specific signaling pathway that impacted ICOS. There is a family of such checkpoint molecules like ICOS, but ICOS has a capability that is not shared with other checkpoint molecules. Its ability to drive antibody differentiation is found only in ICOS, and not in other family members. The connection between ICOS and TBK1 provides important clues to this mystery,” Dr. Kong added.

Researchers in this study discovered that ICOS recruits the signaling TBK1 enzyme to induce high-affinity antibody production. The team was able to identify the region in the ICOS molecule that recruits TBK1, and confirmed it with functional studies — by disrupting this area, scientists prevented the association between ICOS and TBK1, which severely affected Tfh cells and antibody production.

They are now focusing on trying to understand how to diminish ICOS signals as a strategy for autoimmune diseases, and how to increase them to develop more effective vaccines.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length
Click here to read original article


Go to Newer News Go to Older News